H.R. 919

119th Congress

In Committee

Chronic Disease Flexible Coverage Act

Sponsored byRepublican:Rep. Buchanan, Vern [R-FL-16]FL· Introduced 4 February 2025

2

Cosponsors

10

Actions

0

Amendments

2

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Received in the Senate and Read twice and referred to the Committee on Finance.

5 March 2025·1 year ago

Summary

Introduced in House · Updated 7 March 2025

Chronic Disease Flexible Coverage Act

This bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold.

Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold. 

The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to include

  • angiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease;
  • anti-resorptive therapy for individuals with osteoporosis or osteopenia;
  • beta-blockers for individuals with congestive heart failure or coronary artery disease;
  • blood pressure monitors for individuals with hypertension;
  • inhaled corticosteroids and peak flow meters for individuals with asthma;
  • insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes;
  • international normalized ratio testing for individuals with liver disease or bleeding disorders;
  • low-density lipoprotein testing for individuals with heart disease;
  • statins for individuals with heart disease or diabetes; and
  • selective serotonin reuptake inhibitors for individuals with depression. 

The bill provides statutory authority for the IRS's guidance. 

Timeline

10 actions

  1. Received in the Senate and Read twice and referred to the Committee on Finance.

    5 March 2025 · IntroReferral

  2. DEBATE - The House proceeded with forty minutes of debate on H.R. 919.

    4 March 2025 · Floor

  3. Considered under suspension of the rules. (consideration: CR H964-966)

    4 March 2025 · Floor

  4. Mr. Smith (MO) moved to suspend the rules and pass the bill.

    4 March 2025 · Floor

  5. Motion to reconsider laid on the table Agreed to without objection.

    4 March 2025 · Floor

  6. Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964)

    4 March 2025 · Floor

  7. On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964)

    4 March 2025 · Floor

  8. Referred to the House Committee on Ways and Means.

    4 February 2025 · IntroReferral

  9. Introduced in House

    4 February 2025 · IntroReferral

  10. Introduced in House

    4 February 2025 · IntroReferral

Sponsorship

2 cosponsors

Sponsor

Republican:Rep. Buchanan, Vern [R-FL-16]FL

Cosponsors

  • Democrat150%
  • Republican150%

Classification

Policy area

Taxation

Legislative subjects

Health care costs and insuranceHealth care coverage and accessHealth promotion and preventive careIncome tax deductions

Committees

2

  • Ways and Means Committee

    House · Standing

    • Referred To4 Feb 2025
  • Finance Committee

    Senate · Standing

    • Referred To5 Mar 2025

Cosponsor momentum

Cumulative over time

Cosponsors grew from 1 on 4 February 2025 to 2 on 3 March 2025.

Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.